Background/Aims: MicroRNAs (miRNAs) have been shown to participate in the development of pancreatic ductal adenocarcinoma (PDAC) by modulating multiple cellular processes. Increased miR-224 expression enhances proliferation and metastasis in human cancers. This study aimed to investigate the role of miR-224 and its underlying mechanism of action in PDAC. Methods: BrdU, MTT, and cell migration assays were performed to determine cell proliferation, viability, and migration, respectively. The binding sites of miR-224 were identified using a luciferase reporter system, whereas protein expression of target genes was determined by immunoblotting and immunofluorescence analyses. A BALB/c nude mouse xenograft model was used to evaluate the role of miR-224 in vivo. Results: We demonstrated that miR-224 expression was enhanced in PDAC cells and tissues, and was related to migration and proliferation. Noticeably, miR-224 overexpression promoted the proliferation, migration, and metastasis of Panc1 cells, while miR-224 inhibition had the reverse effect on PDAC cells. Moreover, we found that thioredoxin-interacting protein (TXNIP) is a target of miR-224. The results also indicated that miR-224 inversely regulated TXNIP by binding directly to its 3′-untranslated region, which resulted in the activation of hypoxia-inducible factor 1α (HIF1α). Further, either TXNIP re-expression or HIF1α depletion abolished the effects of miR-224 on the proliferation and migration of PDAC cells in vitro and in vivo. Regarding the relationship of TXNIP and HIF1α, we found that TXNIP mediated the nuclear export of HIF1α and its degradation by forming a complex with HIF1α. Conclusion: The miR-224-TXNIP-HIF1α axis may be useful in developing novel therapies for PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a major contributor to cancer-specific mortality, which is catastrophic due to the limited number of treatment options [1, 2] . Although survival has been improved remarkably in patients with PDAC due to the development of therapeutic technologies, its clinical outcome is still unsatisfactory [2] . Contemporary treatments are insufficient for improving clinical outcome [3, 4] . Patients with PDAC usually have no symptoms and present with distant metastasis in organs, such as the lung or liver, or metastasis in proximal organs, including the stomach, intestine, and spleen [5] . Sometimes PDAC can only be identified when the malignancy has progressed to stage IV, subsequent to its surgical excision. Nevertheless, our understanding of relapse and metastasis in PDAC is still insufficient. Hence, the discovery of novel genes linked to metastasis and a better understanding of metastasis are crucial to the treatment of PDAC.
Until now, a large number of microRNAs (miRNAs) have been shown to be potentially effective in the treatment of malignancies [6] [7] [8] [9] . MiRNAs are a group of endogenous evolutionarily conserved small non-coding RNAs, which have been proven to be essential in the development of PDAC, including cell proliferation, cell death, differentiation, angiogenesis, migration, metabolism, and invasion [6, 10, 11] . Recently, miR-224 was demonstrated to be upregulated in cervical cancer [12, 13] . MiR-224 was previously described to be involved in the generation of tumors in hepatocellular carcinoma [14] , and contributes to tumor migration, invasion, and cancer cell proliferation [14, 15] . Moreover, miR-224 is upregulated in colorectal cancer, based on miRNA microarray data [16] . These studies suggest that miR-224 acts as an oncogenic miRNA. However, the biological roles of miR-224 in PDAC remain unknown.
In this study, we aimed to explore the role of miR-224 and its underlying mechanism of action in PDAC. We found that miR-224 expression was upregulated in PDAC and significantly promoted cell proliferation and migration. From a mechanistic point of view, we also demonstrated that miR-224 inhibited the expression of thioredoxin-interacting protein (TXNIP) by targeting its 3′-untranslated region (UTR). Moreover, the downregulation of TXNIP led to the nuclear translocation of hypoxia-inducible factor 1α (HIF1α), an important regulator of growth in PDAC. Our findings provide a new therapeutic target for pancreatic cancer.
Materials and Methods

Cell culture
The Panc1, Miapaca2, AsPc-1, Panc02, and CFPAC1 human PDAC cell lines, and hTERT-HPNE normal pancreatic cells, were obtained from the American Type Culture Collection (Manassas, VA, USA). Another normal human pancreatic cell line, H6c7, was obtained from Kerafast (Boston, MA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (Sigma, St. Louis, MO, USA) at 37 °C under 5% CO 2 .
Tissue specimens A total of 49 pairs of human PDAC tissues and their corresponding matched adjacent non-tumor specimens were collected from the Shanghai Fengxian District Central Hospital, China. For the use of these tissues for research purposes, prior consent was obtained from the patients. Patient anonymity was also preserved.
Cell transfection
A miR-224 mimic, miR-224 inhibitor, pcDNA3.1-TXNIP, and small interfering RNAs (siRNAs) targeting TXNIP and HIF1α were acquired from GenePharma (Shanghai, China). Two different siRNAs were used for TXNIP and HIF1α, respectively. The pGL4.20-HIF1α plasmid was purchased from Addgene (Cambridge, MA, USA). The mutation in the TXNIP chromosomal maintenance 1 (CRM1) site (L294A) was generated using pcDNA3.1-TXNIP by site-directed mutagenesis (Thermo Fisher, Waltham, MA, USA). 
Construction of stable miR-224 and TXNIP overexpressing cell lines
To establish an miR-224 or miR-224 inhibitor overexpressing cell line, the pLV3-224-GFP or pLV3-224i-GFP lentivirus expressing miR-224 or miR-224 anti-oligonucleotides were obtained from GenePharma. Panc1 cells were transduced with pLV3-224-GFP, which we refer to as Panc1-miR-224 cells. AsPc-1 cells were transduced with pLV3-224i-GFP, which were named AsPc-1-miR-224i. The efficiency of miR-224 or miR-224 inhibitor overexpression was detected by quantitative real-time reverse transcription PCR (qRT-PCR). In order to establish the TXNIP stable overexpression cell lines, Panc1 or Panc1 miR-224 overexpressing cells were transfected with pcDNA3.1-TXNIP and subjected to neomycin screening. Stable overexpressing Panc1 cells were further referred to as Panc1-TXNIP and Panc1-miR-224-TXNIP.
Western blotting and immunofluorescence
Cell lysis was performed using RIPA buffer, and protein concentration was measured using the Bradford assay (Bio-Rad, Hercules, CA, USA). Identical amounts of samples were separated by 10-15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were detected with specific antibodies against E-cadherin (#3195; Cell Signaling, BD), vimentin (SC-6260, V9; Santa Cruz), Ki-67 (ab15580; Abcam), TXNIP (K0205-3; MBL), HIF1α (20960-1-AP; ProteinTech), and actin (A2228, Sigma) and the corresponding secondary antibodies. For immunofluorescence, the cells were fixed with paraformaldehyde, permeabilized, and incubated with the primary antibody overnight.
BrdU assay
Cell proliferation was detected using the BrdU incorporation assay (Roche Diagnostics GmbH, Mannheim, Germany). Absorbance was detected at 450 nm.
MTT assay MTT (3-(4, 5-dimethylthiazol-2-y1)-2, 5-diphenyltetrazolium bromide) assay was performed to measure cell viability. After treatment, MTT (10 mL, 5 mg/mL) was added for 2-4 h. After removing the culture medium, 75 mL dimethyl sulfoxide was added and incubated in the dark for 2 h. Then, absorbance was measured at 490 nm.
Cell migration
Cell migration was detected using the Transwell system (Corning, Inc., Corning, NY, USA). The cells (2.0 × 104) were transfected, trypsinized, and seeded into the upper chamber. After incubation for 24 h at 37 °C, the cells that had migrated into the other compartment were fixed with methanol, stained with a 5% crystal violet solution, and counted. Each experiment was conducted with at least 3 replicates, and migrated cells were counted in more than 5 fields in each experiment.
Luciferase assay
The TXNIP 3′-UTR luciferase reporter was transfected into Panc1 cells expressing miR-224, or cotransfected with the miR-224 inhibitor into AsPc-1 cells. Luciferase activity was detected using a dual luciferase (Renilla and firefly) reporter assay system (Promega).
In vivo experiments BALB/c nude mice (4-6 weeks old) were obtained from the Animal Center of the Chinese Academy of Sciences in Shanghai. The mice were randomized into 4 groups (n = 5). Next, 1.0 × 106 Panc1-miR-224, Panc1-miR-NC, Panc1-TXNIP, Panc1-miR-224-TXNIP, AsPc-1-miR-224i, or AsPc-1-miR-NC cells were injected, respectively, into the tail vein to establish a metastatic mouse model. To assess the development of metastatic foci in the lung, the animals were sacrificed at 10 weeks after injection and hematoxylin and eosin (H&E) staining was performed. The animal experiments were approved by the Ethics Review Committee of Shanghai Fengxian District Central Hospital.
Statistical analysis
Data are shown as the mean ± standard deviation (n = 3). GraphPad Prism 6.0 (GraphPad, San Diego, CA, USA) was used to perform a two-tailed Student's t-test with Pearson's correlation analysis. P < 0.05 was considered statistically significant.
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Results
MiR-224 is upregulated in pancreatic cancer clinical tissues and cells
To investigate the role of miR-224 in the development of PDAC, we detected miR-224 expression levels by qRT-PCR. MiR-224 levels were significantly higher in pancreatic cancer tissues than in adjacent tissues (P < 0.001) (Fig. 1A) . We also found that miR-224 was clearly upregulated in aggressive PDAC tissues compared to non-aggressive tissues (P < 0.01, Fig. 1B ). Moreover, we tested the expression levels of miR-224 in various PDAC cell lines and compared them with those observed in the H6c7 and hTERT-HPNE non-tumorigenic epithelial cell lines. Consistently, the levels of miR-224 were significantly increased in all five PDAC cell lines tested compared to the non-tumorigenic epithelial cell lines (Fig. 1C) . Taken together, these data indicate that miR-224 upregulation is a common event in pancreatic cancer tissues. Thus, we propose that miR-224 might be involved in the progression of pancreatic tumors.
MiR-224 stimulates PDAC cancer cell proliferation and migration
To explore further the function of miR-224 in PDAC, miR-224 mimetic (miR) or inhibitor (miRi) was transfected in Panc1 and AsPc-1 cells, which express miR-224 at different levels ( Fig. 1C ). Firstly, we tested cell growth and proliferation in these cell lines using MTT and BrdU assays. MiR-224 transfection significantly increased the mRNA level of miR-224 ( (Fig. 2C&D) . Since epithelial-to-mesenchymal transition has been recognized as an important regulator of cancer metastasis [17] , we investigated whether miR-224 contributes to metastasis in PDAC via the regulation of epithelial-to-mesenchymal transition. We found that miR-224 overexpression promoted the migration of Panc1 cells (Fig. 2E) , whereas miR-224 inhibition by miRi clearly blocked the migration of AsPc-1 cells (Fig. 2F) . Moreover, our western blot analysis demonstrated that miR-224 overexpression suppressed the expression of the epithelial marker E-cadherin, but enhanced the levels of the mesenchymal marker vimentin and the proliferation marker Ki-67 in Panc1 cells (Fig. 2G) . In contrast, loss of miR-224 had the reverse effect on the expression of Ki-67, E-cadherin, and vimentin in AsPc-1 cells (Fig. 2G) . To confirm further the biological function of miR-224 in pancreatic cancer cell metastasis in vivo, AsPc-1 cells stably overexpressing miR-224 inhibitor (Panc1-miR-224i) and control cells (AsPc-1-miR-NC) were injected into the lateral vein of mice. Our results demonstrated that inhibition of miR-224 suppressed pancreatic cancer metastasis to the lung (Fig. 2H) . These findings indicate that miR-224 stimulates PDAC growth and migration.
TXNIP is a direct target of miR-224 in PDAC cells
Previous studies have found that the oncogenic activity of miR-224 is exerted by targeting the 3′-UTR of TXNIP, which suppresses its expression [18] . Here, we discovered that both the mRNA and protein expression levels of TXNIP were significantly lower in all five PC cell lines tested than in normal pancreatic cells (Fig. 3A) . This is in contrast to the expression of miR-224 in these cell lines. Furthermore, the higher expression of miRNA-224 in PDAC cells, such as AsPc-1 and CFAC1, correlated with the lower expression of TXNIP (Fig. 3A) . Notably, an evident inverse correlation was found between the expression levels of miR-224 and TXNIP mRNA in PDAC tissues (P < 0.001, Fig. 3B ), suggesting that TXNIP might be a target of miR-224 in PDAC. To confirm this result, we further determined TXNIP expression in various PDAC cells treated with miR or miRi. Accordingly, TXNIP was also downregulated by miR-224 under these conditions, but its expression increased when miR-224 was inhibited (Fig. 3C&D) . Next, miR-224 overexpression was found to decrease luciferase activity, while luciferase activity was unchanged when the 3′-UTR sequences in the sites complementary to the seed region of miR-224 were mutated (Fig. 3E) . Further, miRi significantly increased luciferase activity when the constructs were co-transfected into cells. However, luciferase activity did not change when the 3′-UTR sequences in TXNIP, in the seed region of miR-224, were mutated (Fig. 3E) . These data show that TXNIP is the target of miR-224 in PDAC cells.
TXNIP mediates the effects of miR-224 in vitro and in vivo
Since TXNIP is a target of miR-224 in the progression of PDAC, we further speculated that this oncogenic behavior is dependent of the inhibition of TXNIP. The depletion of TXNIP using two different siRNAs suppressed the expression E-cadherin, but augmented the expression of vimentin and Ki-67 in Panc1 cells (Fig. 4A and Fig. S2A) . Accordingly, the silencing of TXNIP promoted cell proliferation and migration in Panc-1 cells (Fig. 4B&C and  Fig. S2B&C ), which had similar effects with miR-224 overexpression. Furthermore, the co- Our results demonstrated that the miR-224 overexpression group displayed more metastasis, observed as lung nodules, when examined microscopically (Fig. 4G) . However, the co-expression of TXNIP and miR-224 resulted in a reduction in the number of lung nodules (Fig. 4G) . Taken together, our data demonstrate that miR-224 leads to PDAC growth and migration by targeting and suppressing TXNIP.
MiR-224 upregulates HIF1α via the TXNIP pathway
HIF1α is a crucial factor in the induction of tumor proliferation, migration, and metastasis [19] , and it is degraded by the von Hippel-Lindau protein (pVHL) under normoxia [20] . Here, we also demonstrated that the depletion of TXNIP by siRNA increased the expression of HIF1α in Panc1 cells (Fig. 5A) . In contrast, the enhanced expression of TXNIP compromised the induction of HIF1α following miR-224 transfection (Fig. 5B) . However, no significant changes in HIF1α mRNA levels were observed upon TXNIP knockdown or miR-224 transfection (Fig. 5C ), suggesting that TXNIP and miR-224 modulate HIF1α at the protein level. Accordingly, the downregulation of HIF1α using an miR-224 inhibitor could be rescued by pretreatment with the protease inhibitor MG132 (Fig. 5D ). Previous studies have indicated that TXNIP is associated with the β-domain of pVHL and promotes the degradation of HIF1α independently of hypoxia [20] . We therefore tested the interaction 
between TXNIP and HIF1α and the ubiquitination status of HIF1α, and found that the miR-224 inhibitor enhanced the interaction between TXNIP and HIF1α and the ubiquitination of HIF1α upon MG132 pretreatment (Fig. 5E ). However, TXNIP knockdown abolished the ubiquitination of HIF1α, indicating that the interaction between TXNIP and HIF1α promotes its degradation. As the CRM1 binding site (Leu294) in TXNIP is important for the formation of the TXNIP-pVHL-HIF1α complex [ 2 1 ] , we transfected AsPc-1 cells with the TXNIP construct or the TXNIP construct containing the CRM1 binding site mutation. We found that the enhanced expression of wild-type TXNIP increased the interaction with HIF1α and HIF1α ubiquitination, which was absent when mutant TXNIP was transfected (Fig. 5F ). Furthermore, miR-224 transfection led to HIF1α stabilization and translocation into the nucleus, which was abolished by co-transfection with wild-type TXNIP, but not mutant TXNIP (Fig. 5G) . These findings suggest that miR-224 suppresses TXNIP expression to release and stabilize HIF1α.
HIF1α is necessary for miR-224-mediated growth
Finally, we determined whether HIF1α is necessary for miR-224-mediated cell proliferation and migration in PDAC. As predicted, miR-224 overexpression in Panc1 cells increased the expression of HIF1α, which was correlated with the augmentation of cell proliferation and migration (Fig. 6A-C and Fig. S3 ). In contrast, knockdown of HIF1α compromised the growth induced by transfection with miR-224 (Fig. 6A-C and Fig. S3 ). Conversely, suppression of miR-224 by its inhibitor decreased HIF1α expression, cell proliferation, and migration ( Fig. 6D-F) , which was reversed by the enhanced expression of HIF1α (Fig. 6E-F) . These results indicate that miR-224 increases HIF1α levels and activity by downregulating TXNIP, which is essential for PDAC cell growth and migration.
Discussion
The distinct expression of miRNAs between malignant and normal specimens or among groups of malignant specimens with a favorable or unsatisfying prognosis has been used to obtain miRNA signatures with promising predictive and/or prognostic values [22, 23] . MiRNA profiling of PDAC tissues has identified several hundreds to thousands of miRNAs associated with tumor progression [6] . However, only a few studies have described the correlation between miR-224 and pancreatic cancer. Here, we showed that miR-224 expression was upregulated in aggressive tumor samples compared with nonaggressive tumor samples. Furthermore, our results demonstrated that miR-224 promoted PDAC cell proliferation and migration in vitro, as well as metastasis to the lung in vivo. Thus, miR-224 acts as an oncogene to promote the progression and metastasis of pancreatic cancer, which is consistent with previous studies [13, 24] . Although miR-224 is overexpressed in various cancers and promotes cancer progression [25] , the mechanism underlying the role of this miRNA in cancer is understood poorly. In this study, a novel mechanism underlying the role of miR-224 was elucidated, namely that miR-224 promotes PDAC cell growth through miR-224-TXNIP-HIF1α signaling. A previous report showed that E2F1 modulates the expression of miR-224 by targeting TXNIP, which can drive cancer metastasis in melanoma [18] . However, the mechanism through which TXNIP inhibits cancer progression was not addressed clearly. In this study, we have also shown that miR-224 targets TXNIP and suppresses its expression in pancreatic cancer, which may promote PDAC growth. Furthermore, the suppression of TXNIP by miR-224 leads to the nuclear translocation of HIF1α, which is an important stimulator of cancer progression.
The loss of TXNIP has been shown to correlate with the advanced stage of breast, gastric, colorectal, and bladder cancers [20, 26, 27] . However, TXNIP genetic alterations, such as deletions, translocations, or somatic mutations, have not been found in these cancers [28] . In this study, we found that miR-224 targets TXNIP and leads to its suppression in PDAC. TXNIP has also been reported as a suppressor of metastasis [18, 29] . Consistent with these findings, we observed that the enhanced expression of TXNIP reduced miR-224-induced cell growth and metastasis in PDAC. TXNIP was primarily recognized as a thioredoxin-binding protein that inhibits thioredoxin [30] . Since thioredoxin promotes tumor progression by inducing angiogenesis [31] and inhibiting apoptosis [32] , TXNIP has great potential as a tumor suppressor gene. A previous study also found that miR-337 overexpression led to TXNIP silencing, and decreased the levels of intracellular reactive oxygen species (ROS), which activated HIF1α and TWIST [33] . Nevertheless, recent research has revealed that TXNIP plays a crucial role in redox-independent signaling [21] . TXNIP was found to inhibit glucose uptake independent of thioredoxin binding, which was important for the survival of thyroid cancer cells [34] . Interestingly, several studies have also shown that the overexpression of TXNIP inhibited HIF-mediated reporter activity in various cancer cells [20, 33, 35] . Moreover, they found that the CRM1 region of TXNIP binds the nuclear transcription factor HIF1α and the ubiquitin ligase pVHL. The TXNIP-pVHL-HIF1α complex results in the degradation of HIF1α [24] . In accordance with these results, our study also showed that TXNIP negatively regulated HIF1α, independently of its interaction with thioredoxin and ROS, as no obvious change in HIF1α mRNA levels was observed. Instead, our results suggest that TXNIP can form a complex with HIF1α, which leads to HIF1α degradation and inhibition of its nuclear translocation.
The modulation of HIF1α concentration is essential to manage the expression of diverse genes involved in the hypoxic reaction, vessel generation, oxygen transport, and glucose metabolism, which promote migration, growth, and tumor invasion [36, 37] . In cells, HIF1α is regulated through various pathways, such as transcription, translation, and posttranslational mechanisms, protein-protein interactions, and degradation [36, 37] . Besides hypoxia mimetics, various hypoxic miRNAs that affect HIF1α expression have been identified [38, 39] . Here, we showed that miR-224 elevated HIF1α levels and activated HIF1α by directly targeting TXNIP. The co-expression of TXNIP blocks the induction of growth and the upregulation of HIF1α induced by miR-224. However, as opposed to previous studies, which showed that miR-373 activated HIF1α by ROS scavenging, our results suggested that miR-224 induces HIF1α expression by enhancing its nuclear translocation and stabilization. It has been shown that HIF1α localization and degradation occurs in a cell type-dependent Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry manner and varies in response to different stimuli [40, 41] . In transformed HeG2 cells, HIF1α degradation mainly occurred in the cytoplasm, while in primary endothelial cells, it occurred in the nucleus and cytoplasm. Therefore, our data suggest that the miR-224-TXNIP-HIF1α axis is important for PDAC cell proliferation and migration, which creates novel opportunities for cancer therapeutics. In summary, our results suggest that miR-224 drives pancreatic cancer cell proliferation and migration. From a mechanistic perspective, miR-224 promotes cancer progression and metastasis via the miR-224-TXNIP-HIF1α axis in PDAC. Components of this axis may be utilized as potential therapeutic targets and biomarkers for PDAC.
